Filing Flows › Ovid Therapeutics (OVID) › Q2 2025
Ovid Therapeutics (OVID) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Ovid Therapeutics (OVID) reported revenue of $6.3M for the second quarter 2025 (Q2 2025), up 37-fold from a year earlier and up 48-fold from the quarter before. Operating margin was -80.9%, net loss $4.7M (74.7% of revenue).
Ovid Therapeutics, Q2 2025: revenue $6.3M (37× year over year), operating margin -80.9%, net loss $4.7M, operating cash flow −$4.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.3M | 48× | 37× |
| Operating profit | −$5.1M | — | — |
| Net earnings | −$4.7M | — | — |
| Operating cash flow | −$4.8M | — | — |
What changed
Revenue was $6.3M in Q2 2025, up 3611% year over year and up 4725% from the previous quarter.
Operating costs exceeded revenue by $5.1M, an operating margin of -80.9%. Total costs fell 45% while revenue rose 3611%. The quarter ended with a net loss of $4.7M, narrower than the previous quarter's $10.2M loss.
Operating cash flow was −$4.8M. Non-cash charges added back $99K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items used $1.4M.
Questions
What was Ovid Therapeutics' revenue in the second quarter 2025?
Ovid Therapeutics (OVID) reported revenue of $6.3M for the second quarter 2025 (Q2 2025), up 37-fold from a year earlier and up 48-fold from the quarter before.
Was Ovid Therapeutics profitable in the second quarter 2025?
Operating loss was $5.1M (-80.9% of revenue) and net loss $4.7M.
Source: Ovid Therapeutics 10-Q on SEC EDGAR.